Type 2 Diabetes Mellitus Clinical Trial
— DIDMOfficial title:
Nutrition Studies and Dietary Intervention in Individuals With Type 2 Diabetes Mellitus of Chinese, Malay and Indian Ethnicity
Lifestyle modification, in particular adopting an appropriate dietary pattern, is generally
accepted as the cornerstone for the treatment of people with type 2 diabetes mellitus
(T2DM). Consumption of low glycaemic index (GI) meals have been shown to improve glycaemic
control, lipid profile and reduced systemic inflammation. However, these studies and
international evidence-based nutritional recommendations are principally based on people of
European ethnicity consuming fairly typical "western" diets. There are few published
controlled dietary intervention studies which have attempted to determine appropriate
dietary patterns for the treatment of diabetes amongst populations consuming rice-based
diets.
HYPOTHESIS
1. The glycaemic response over 6 days as measured by CGMS will have a lower mean glucose
level and postprandial increase in individuals consuming the LGI compared with the SDI
meal plan.
2. A LGI meal plan is acceptable and participants will adhere and comply to the diet to
the same level as those receiving the SDI meal plan.
3. Glycaemic and metabolic parameters as measured by integrated area under the curve
(IAUC) of glucose and insulin are lower after a single meal comprising of LGI than
compared with an SDI meal.
4. The effect of a single meal of LGI reduces appetite and increases satiety compared with
a meal of SDI.
Status | Recruiting |
Enrollment | 160 |
Est. completion date | August 2014 |
Est. primary completion date | May 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 45 Years to 64 Years |
Eligibility |
Inclusion Criteria: 1. Be willing and able to comply with study procedures and give written informed consent 2. Have established diagnosis of type 2 diabetes* of more than 1 year on diet treatment or oral anti-diabetic therapy 3. Male or female, aged 45 to 64 years inclusive 4. HbA1c of 7.0 - 10.0% (inclusive) within the last 3 months or at screening 5. Stable glycaemic control 6. Patients with concurrent illnesses if medically stable for 6 months prior to screening visit, based on the clinical judgement of the investigator 7. Be on stable therapy (no significant change to therapy in last 3 months) 8. No hospitalization or surgery in the past 6 months 9. No use of corticosteroids in the last 6 months 10. Not pregnant 11. Urea <30 mmol/L and estimated GFR >= 60ml/min 12. Be willing to prepare and adhere to the meal plans and consume at least two meals at home per day. 13. Be willing and able to undertake blood glucose monitoring, continuous glucose monitoring. - Subjects with Type 2 DM should have been diagnosed at least 1 years prior to the screening visit and should not have T1DM, MODY or secondary diabetes e.g. diabetes secondary to chronic pancreatitis Exclusion Criteria: 1. Significant medical conditions which in the Investigator's opinion would confound interpretation of the results, including but not limited to: current symptomatic cardiovascular disease, macroalbuminuria (dipstick positive proteinuria on more than 1 consecutive occasion) or renal impairment (serum creatinine above 120 umol/l), cancer, overt liver disease other than Non Alcoholic Steatohepatitis (liver enzyme levels less than 3 times upper limit of normal) or gastroparesis. 2. Recent changes in weight of >5% over the past 6 months 3. Significant changes in diet over the past 6 months 4. Any use of weight reducing drugs, or on medications such as alpha-glucosidase inhibitors or insulin currently or in the past 6 months 5. Any surgery (and bariatric surgery) in the past 6 months 6. Any use of investigational drugs in the past 6 months 7. Any serious illness requiring hospitalization in the past 6 months 8. Any use of corticosteroids in the past 6 months 9. Ongoing infection, or condition that interfered with nutrient digestion, absorption, metabolism or excretion (including gastroparesis) 10. Allergy or intolerant to the ingredients or any of the food items in the intervention diet or to paracetamol/ acetaminophen |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Singapore | National University Hospital | Singapore |
Lead Sponsor | Collaborator |
---|---|
National University Hospital, Singapore | National Medical Research Council (NMRC), Singapore |
Singapore,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Average mean glucose levels and variability | To assess the intermediate effects on glycaemia and metabolic response to a meal plan comprising of LGI compared with a SDI meal plan | 2 weeks | No |
Secondary | HBA1C | To assess acceptability and compliance to the intervention meal plan To assess the intermediate effects of glycaemia |
3 and 6 months | No |
Secondary | Glucose and Insulin Levels | To assess glycemic and metabolic response to a mixed meal | 1 week | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
Completed |
NCT02226003 -
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
|
Phase 3 |